TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Modalis Therapeutics Corporation ( (JP:4883) ) has shared an update.
Modalis Therapeutics Corporation announced the issuance of 2,300 new shares as part of a post-delivery restricted-stock-based remuneration plan. This initiative is designed to align the interests of employees and directors with shareholders by offering stock compensation, thereby aiming to sustainably increase the company’s medium- to long-term corporate value. The impact on the total number of issued shares is minimal, ensuring the plan’s reasonableness and alignment with corporate goals.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation operates in the biotechnology industry, focusing on developing innovative therapies using gene modulation technology. The company is listed on the Tokyo Stock Exchange and aims to enhance its corporate value through strategic initiatives.
Average Trading Volume: 1,927,728
Technical Sentiment Signal: Sell
Current Market Cap: Yen5.4B
See more insights into 4883 stock on TipRanks’ Stock Analysis page.